1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
This page is not indexed by search engines while we improve data quality.
Kato Mitsunori — Human Necessities
Kato Mitsunori holds 14 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Kato Mitsunori |
| Technology | Human Necessities |
| Patents in slice | 14 |
| Recent patents in slice | 0 |
| First year | 2017 |
| Last year | 2020 |
Representative patents
Notable publications linking Kato Mitsunori to Human Necessities.
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US-10208018-B2 · Feb 19, 2019 · US
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US-10208018-B2 · Feb 19, 2019 · US
Recent filings
Latest patents from Kato Mitsunori in Human Necessities.
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US-10774065-B2 · Sep 15, 2020 · US
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US-10208018-B2 · Feb 19, 2019 · US
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US-10208018-B2 · Feb 19, 2019 · US
Related pages
Navigate to parent entity pages.